By Pooja Toshniwal PahariaMay 20 2024Reviewed by Lily Ramsey, LLM In a recent study published in Nature, researchers developed the MK-801 bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models of metabolic illness by combining N-methyl-D-aspartate receptor antagonism with glucagon-like peptide-1 receptor antagonism.
NMDA receptor inhibitors, like MK-801 and memantine, lead to weight reduction in rats and reduced palatable food choices in rodents and non-human primates. These antagonists also inhibit binge eating in humans. Researchers developed MK-801 by peptide cleavage and purification following disulfide linker production and evaluated the compound's ability to transmit protraction. They functionalized the disulfide linker after reacting with an amine-containing medication.
They conducted metabolic phenotyping and indirect calorimetry investigations using DIO C57BL/6J mice. Following dosage determination, they evaluated the metabolic impacts in vivo by comparing MK-801-GLP-1 to the MK-801 and vehicular therapies. In numerous rodent models representing metabolic diseases and obesity, treatment with the MK-801-GLP-1 combination significantly corrected obesity, diabetes, and dyslipidemia.
Glucagon-Like Peptide-1 Obesity Receptor Agonist Brain Cation Compound Dyslipidemia Food GLP-1 Glucose Hyperglycemia Hypothalamus Molecule Weight Loss
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Drug targeting RNA modifications shows promise for treating neuroblastomaNeuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% of patients do not survive.
Source: medical_xpress - 🏆 101. / 51 Read more »
Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolismLate-breaking data from the ENGULF trial showed that a novel dual-action thrombectomy device was effective and safe in treating acute pulmonary embolism (PE). The safety and effectiveness results were presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and simultaneously published in JSCAI.
Source: medical_xpress - 🏆 101. / 51 Read more »
Researchers reveal a new approach for treating degenerative diseasesProteins are the workhorses of life. Organisms use them as building blocks, receptors, processors, couriers and catalysts. A protein's structure is critical to its function. Malformed proteins not only fail to carry out their tasks, they can accumulate and eventually gum up the inner workings of cells.
Source: medical_xpress - 🏆 101. / 51 Read more »
ZIP7: A novel target for treating degenerative diseases associated with misfolded proteinsProteins are the workhorses of life. Organisms use them as building blocks, receptors, processors, couriers and catalysts.
Source: NewsMedical - 🏆 19. / 71 Read more »
Psilocybin found to be more effective than controls for treating depression symptomsPsilocybin - the active ingredient in 'magic' mushrooms - is a more effective treatment for symptoms of depression than controls, providing further support for its potential as an antidepressant, suggests a study published by The BMJ today.
Source: NewsMedical - 🏆 19. / 71 Read more »
Disgraced former NHS surgeon seen treating tot as Scots victims wait for justiceSam Eljamel has been treating babies and children after fleeing Scotland.
Source: Daily_Record - 🏆 9. / 89 Read more »